Glioblastoma (GBM) is the most common and aggressive form of primary brain cancer. Worldwide, more than 300,000 people were diagnosed with brain or central nervous system cancer in 2020, and 250,000 died from their disease (WHO, 2020).
The mainstay of treatment for GBM typically comprises surgical resection, followed by combined radiotherapy and chemotherapy.
However, despite such treatment, most patients experience recurrence of their GBM, with an expected survival duration of approximately 15 months from diagnosis (Fernandes et al, Current Standards of Care in Glioblastoma Therapy, 2017).
L-type amino acid transporter 1 (LAT-1) is a heterodimeric membrane transport protein that is typically highly expressed in GBM.
Telix is investigating LAT-1 as a potential target for GBM theranostics.
For more information on Telix’s clinical trials in brain cancer please see trial descriptions below, clickable through to clinical trial database where registered: